For Clinics

MAPS-Funded MDMA Therapy for PTSD Is Back at the FDA, Without a New Phase 3 Trial

MDMA assisted therapy for PTSD appears to be back in front of the FDA. Psychedelic Alpha reported on August 9 that Resilient Pharmaceuticals has resubmitted the application the agency declined two years ago. MAPS responded to that report the next day without independently confirming it. The detail that matters is not the resubmission. It is […]

IV Ketamine Could Get Its First FDA Psychiatric Indication. Here Is What Would Actually Change

Last reviewed and updated: August 13, 2026. Headlines about the FDA and ketamine will multiply this year. Most operators will read them wrong. Some describe a generic manufacturing application. One concerns NRX-100, a specific IV ketamine product pursuing a psychiatric indication. That program could change how clinics approach coverage, marketing and protocols. Knowing which is […]

England Has a Recreational Ketamine Crisis. Here Is How American Clinics Keep It From Happening Here

In one Manchester treatment cohort, 64 percent of the people being treated for ketamine problems were under 18. Forty two percent were between 13 and 16. That is what a recreational ketamine crisis looks like once it has fully arrived, and England is living in one. America is not, and the reason has less to […]

Psilocybin Sessions for PTSD Are Mostly Silent. The Argument About What to Call Them Is Not

A new analysis found psilocybin dosing sessions for PTSD are silent 78 percent of the time. Why the authors want the name changed, and who benefits if it is.

Cluster Headaches Have New Trial Data. Ketamine Clinics Should Be Paying Attention

Two 2024 randomized trials cut cluster headache attacks with pulse dose psilocybin. Where ketamine sits, why these patients overlap with yours, and the access gap.

Ketamine Patients and GLP-1 Patients Are Often the Same People

47 percent of peptide clinics now offer a GLP-1. Depression, drinking and metabolic disease cluster in the same patients.

Psychedelic Trials Are Going Intravenous. Ketamine Clinics Already Have That Room

A new trial of intravenous psilocin points to where psychedelic delivery is heading. Ketamine clinics already have the infusion rooms and titration skills it needs.

Three Psychedelic Companies Analysts Say Could Be Acquired Next

The Deal That Changed the Temperature Eli Lilly agreed in July to pay up to $3.8 billion for AtaiBeckley. That number reset expectations across psychedelic medicine. Analysts now openly discuss which company gets bought next. For clinic owners, the question matters more than it might appear. The companies being courted are building the treatments your […]

Five Months After Lilly’s B12 Warning, 1 in 7 Tirzepatide Clinics Still Advertises the Combination

Eli Lilly warned in March that compounded tirzepatide with B12 forms an uncharacterized impurity. We checked 800 clinic websites to see how many still advertise the combination.

The FTC Just Sued Hims & Hers Over Tracking Pixels. Your Clinic Probably Runs Them Too

The FTC, Utah and California sued Hims & Hers over health data sharing, billing and cancellations. The practices named are common at cash pay clinics.